Advanced/recurrent head & neck squamous-cell carcinoma
head and neck squamous-cell carcinoma
RECURRENT DISEASE, METASTATIC DISEASE
Of patients with head and neck squamous-cell carcinoma, up to 20–30% develop metastatic disease and up to 40–60% experience locoregionally recurrent disease.Systemic therapy alone is associated with limited response rate and survival.Quad-shot (QS) radiotherapy (RT) is a low-dose palliative regimen that provides symptomatic relief and local control.